Form 4: MPM BioVentures 2014, L.P. Exercises Warrants and Disposes of Shares in Werewolf Therapeutics, Inc.

MPM BioVentures 2014, L.P. exercised warrants to purchase shares of Werewolf Therapeutics, Inc. common stock and subsequently disposed of a portion of those shares to cover the exercise price.

Summary

• On March 27, 2025, MPM BioVentures 2014, L.P. exercised warrants to acquire 22,758 shares of Werewolf Therapeutics, Inc. common stock at a price of $0.09 per share.
• The exercise price was paid on a cashless basis, resulting in the withholding of 1,963 shares by the company.
• MPM BioVentures 2014, L.P. then sold 1,963 shares at $1.05 per share.
• Following these transactions, the total number of shares beneficially owned by MPM BioVentures 2014, L.P. and related entities is 3,208,793.
• The warrants exercised were immediately exercisable.

Sentiment

Score: 6

Explanation: The document is a standard SEC filing detailing transactions by a major shareholder. It doesn't inherently convey positive or negative sentiment, but reflects routine investment management activity.

Industry Context

This filing reflects the activity of a major shareholder, MPM BioVentures, in managing its investment in Werewolf Therapeutics. Such transactions are common in the biotech industry, where venture capital firms often hold significant stakes in companies.

Comparison to Industry Standards

• Cashless warrant exercises are a standard practice in the biotech industry, allowing investors to exercise their warrants without needing to provide additional cash.
• The filing is consistent with standard SEC reporting requirements for changes in beneficial ownership by insiders and major shareholders.

Stakeholder Impact

• The transaction may have a minor impact on shareholders due to the increase in the number of outstanding shares and the sale of shares on the open market.

Key Dates

Keywords

Werewolf Therapeutics, MPM BioVentures, Form 4, Beneficial Ownership, Warrants, HOWL, Securities